EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial

All NewsJune 11, 2025

Adial refines Phase 3 plans for AD04 in Alcohol Use Disorder, focusing on genetic subgroups and leveraging Cytel’s advanced trial design expertise.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent